

Technology Advisory Committee C Interests Register

Topic: brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

Publication Date: 7 May 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC Committee Member	Direct- financial	Satish works for, and has shares and stock options in, Regeneron, a pharmaceuticals/biotech company. Regeneron is developing REGN5837 CD22xCD28 and Odronextamab CD20xCD3 bispecific antibodies for certain B cell lymphomas including non-Hodgkin lymphoma. Odronextamab has been approved by EMA for certain relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL).	11/10/2024	It was agreed that Satish's declaration would not prevent him from participating in discussions on this appraisal.
Michael Chambers	TAC Committee Member	Direct- financial	Michael was funded by Takeda (until September 2022) to participate in EU Innovative Medicines Initiative projects - this did not concern specific Takeda products. Michael has participated in an advisory panel for Pfizer in an unrelated disease area, prostate cancer.	11/10/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	TAC Committee Member	Direct- financial	Kate has provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	12/10/2024	It was agreed that Kate's declaration would not prevent her from participating in discussions on this appraisal.
Elizabeth Thurgar	TAC Committee Member	Direct- financial	In the past 12 months, Elizabeth has provided consultancy advice to Takeda (the Company) in the following unrelated conditions: Dravet syndrome, Lennox Gastaux syndrome, short bowel syndrome. In the past 12 months, Elizabeth has provided consultancy advice to JNJ, which owns Janssen-Cilag, a listed comparator company, in an unrelated condition, multiple myeloma. Elizabeth currently works with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.	14/10/2024	It was agreed that Elizabeth's declaration would not prevent her from participating in discussions on this appraisal.
Dr Prithwiraj Das	TAC Committee Member	Non-financial	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. He has not worked on	30/10/2024	It was agreed that Prithwiraj's declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			these products/indications in the last 12+ months. He consulted Takeda Global on global access considerations for an unrelated indication for a few months, ending on 10 December 2023.		participating in discussions on this appraisal.
Cathy Burton	Clinical Expert	Direct- financial	Cathy has received financial support from Takeda to attend the International Conference of Malignant Lymphoma June 2023 – accommodation, travel and registration. She attended Takeda advisory boards in November 2023 and January 2024. Takeda is supporting her to attend the International Symposium in Hodgkin Lymphoma in October 2024 and paying an honorarium.	21/02/2024	It was agreed that Cathy's declaration would not prevent her from providing expert advice to the committee.
Graham Collins	Clinical Expert	Direct- financial	Graham has received honoraria for participation in advisory boards, and for speaker work, for Takeda. He has received research support from Pfizer.	21/02/2024	It was agreed that Graham's declaration would not prevent him from providing expert advice to the committee.
Susannah wood	Patient Expert	Direct- financial	Susannah's nominating organisation and employer Lymphoma Action has	22/02/2024	It was agreed that Susannah's declaration

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			received funding from Takeda and Kyowa Kirin.		would not prevent her from providing expert advice to the committee.